Literature DB >> 15371166

Early-phase alcoholic liver disease: an update on animal models, pathology, and pathogenesis.

Shashi Ramaiah1, Chantal Rivera, Gavin Arteel.   

Abstract

Alcoholic liver disease (ALD) remains to be one of the most common etiology of liver disease and is a major cause of morbidity and mortality worldwide. The pathologic stages of ALD comprises of steatosis, steatohepatitis, and fibrosis/cirrhosis. Steatosis and steatohepatitis represents the early phase of ALD and are precursor stages for fibrosis/cirrhosis. Numerous research efforts have been directed at recognizing cofactors interacting with alcohol in the pathogenesis of steatosis and steatohepatitis. This review will elucidate the constellation of complex pathogenesis, available animal models, and microscopic pathologic findings mostly in the early-phase of ALD. The role of endotoxin, reactive oxygen species, alcohol metabolism, and cytokines are discussed. Understanding the mechanisms of early-phase ALD should provide insight into the development of therapeutic strategies and thereby decrease the morbidity and mortality associated with ALD.

Entities:  

Mesh:

Year:  2004        PMID: 15371166     DOI: 10.1080/10915810490502069

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  22 in total

1.  Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice.

Authors:  Kristofer S Fritz; James J Galligan; Matthew D Hirschey; Eric Verdin; Dennis R Petersen
Journal:  J Proteome Res       Date:  2012-02-21       Impact factor: 4.466

Review 2.  Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism.

Authors:  Juliane I Beier; Gavin E Arteel
Journal:  Exp Biol Med (Maywood)       Date:  2012-01

3.  Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3.

Authors:  Sung Hwan Ki; Oygi Park; Mingquan Zheng; Oriol Morales-Ibanez; Jay K Kolls; Ramon Bataller; Bin Gao
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

4.  Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice.

Authors:  Sayaka Inokuchi; Hidekazu Tsukamoto; EekJoong Park; Zhang-Xu Liu; David A Brenner; Ekihiro Seki
Journal:  Alcohol Clin Exp Res       Date:  2011-04-04       Impact factor: 3.455

Review 5.  Inflammation in alcoholic liver disease.

Authors:  H Joe Wang; Bin Gao; Samir Zakhari; Laura E Nagy
Journal:  Annu Rev Nutr       Date:  2012-04-18       Impact factor: 11.848

6.  Saikosaponin D Inhibits the Proliferation and Promotes the Apoptosis of Rat Hepatic Stellate Cells by Inducing Autophagosome Formation.

Authors:  Hong Jiang; Jia Liu; Kun Zhang; Qingxin Zeng
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-18       Impact factor: 2.629

7.  Liver proteome analysis in a rodent model of alcoholic steatosis.

Authors:  Billy W Newton; William K Russell; David H Russell; Shashi K Ramaiah; Arul Jayaraman
Journal:  J Proteome Res       Date:  2009-04       Impact factor: 4.466

Review 8.  Rodent models of alcoholic liver disease: of mice and men.

Authors:  Elizabeth Brandon-Warner; Laura W Schrum; C Max Schmidt; Iain H McKillop
Journal:  Alcohol       Date:  2012-09-07       Impact factor: 2.405

9.  Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.

Authors:  Jin-Hyung Lee; Atrayee Banerjee; Yoshi Ueno; Shashi K Ramaiah
Journal:  Toxicol Sci       Date:  2008-08-14       Impact factor: 4.849

10.  Susceptibility of L-FABP-/- mice to oxidative stress in early-stage alcoholic liver.

Authors:  Rebecca L Smathers; James J Galligan; Colin T Shearn; Kristofer S Fritz; Kelly Mercer; Martin Ronis; David J Orlicky; Nicholas O Davidson; Dennis R Petersen
Journal:  J Lipid Res       Date:  2013-01-28       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.